In a terminal animal experiment, 83.3% of mice carrying mammary adenocarcinoma died within 24 days under administration of the monovalent anti-MMR VHHs alone, while all mice survived for longer than 35 days after co-injection with 100-fold unlabelled bivalent α-MMR VHHs. This evidence concerns the gene MRC1 and breast adenocarcinoma.